Cerevance

69 articles about Cerevance

• Cerevance Announces First-in-Human Dosing of CVN424 for the Treatment of Parkinson’s Disease

  9/25/2018

  Cerevance today announced the start of dosing in a Phase I first-in-human clinical trial of CVN424, an oral compound being developed for symptomatic treatment of Parkinson’s disease.

• Cerevance Kicks Off 2018 with Additional $10 Million of Infusions

  2/21/2018

  Cerevance, a drug discovery and development company focused on brain diseases, today announced that it has received an additional equity investment as well as a non-dilutive cash payment in the first six weeks of 2018 totaling more than $10 million.

• Cerevance Appoints David H. Margolin, MD, PhD as Senior Vice President of Clinical and Translational Medicine

  11/27/2017

  Prior to joining Cerevance, Dr. Margolin served in several leadership roles at Sanofi-Genzyme over a 14-year period.

• Trailblazer in Molecular Genetics and Neuroscience, Jeremy Nathans, MD, PhD, to Advise Cerevance

  10/24/2017

  Cerevance announced that Jeremy Nathans, M.D., Ph.D., has joined the company as a senior-level scientific advisor.

• Cerevance Licenses Human Brain Tissue Profiling Technology from The Rockefeller University

  10/17/2017

  Cerevance today announced that it has signed an agreement with The Rockefeller University to license a novel technology for profiling specific cell populations in human brain tissue.

• Harvard’s Rudolph Tanzi, Ph.D., A Leader In Alzheimer’s Disease Genetics, Joins Cerevance’s Advisory Board

  10/12/2017

• Stanford Neuroscientist, Robert Malenka, M.D., Ph.D., To Advise Cerevance

  10/5/2017

• Dementia Discovery Fund To Invest $5 Million In Cerevance To Seek New Treatments For Dementia

  5/3/2017

• Cerevance Launches With $36 Million and 25 Former Takeda Employees on Its Roster

  12/2/2016